Knight Therapeutics Inc. KHTRF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.53% | 34.27% | 76.32% | 37.98% | 30.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.53% | 34.27% | 76.32% | 37.98% | 30.46% |
| Cost of Revenue | 3.73% | 19.26% | 55.98% | 21.50% | 37.79% |
| Gross Profit | 20.72% | 55.22% | 107.37% | 61.05% | 22.77% |
| SG&A Expenses | 21.51% | 30.47% | 37.86% | 40.62% | 20.56% |
| Depreciation & Amortization | -5.61% | 25.37% | 62.03% | 30.69% | 36.83% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.61% | 25.64% | 54.07% | 27.64% | 34.43% |
| Operating Income | 744.67% | 3,682.40% | 299.87% | 310.66% | -80.03% |
| Income Before Tax | -149.76% | 86.53% | 3,818.85% | 43.11% | -412.20% |
| Income Tax Expenses | -214.68% | 142.09% | 141.02% | 183.21% | 254.78% |
| Earnings from Continuing Operations | 30.40% | 73.38% | 530.54% | -17.18% | -4,517.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.40% | 73.38% | 530.54% | -17.18% | -4,517.98% |
| EBIT | 744.67% | 3,682.40% | 299.87% | 310.66% | -80.03% |
| EBITDA | 16.06% | 101.53% | 363.16% | 155.96% | 9.90% |
| EPS Basic | 29.35% | 73.03% | 537.25% | -16.25% | -4,700.00% |
| Normalized Basic EPS | 103.92% | 199.40% | 71,800.00% | 189.87% | -0.97% |
| EPS Diluted | 26.21% | 73.72% | 582.01% | -10.88% | -4,933.33% |
| Normalized Diluted EPS | 103.92% | 199.40% | 71,500.00% | 189.87% | -0.97% |
| Average Basic Shares Outstanding | -1.43% | -1.44% | -1.19% | -1.19% | -1.46% |
| Average Diluted Shares Outstanding | -1.43% | -1.44% | -1.15% | -1.07% | -1.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |